• Publications
  • Influence
Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro.
BACKGROUND & AIMS The activated pregnane X receptor is antifibrogenic in rodent chronic liver injury in vivo models. The aim of this study was to determine the effects of human pregnane X receptorExpand
  • 84
  • 6
Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells
Gliotoxin has been shown to promote a reversal of liver fibrosis in an animal model of the disease although its mechanism of action in the liver is poorly defined. The effects of gliotoxin onExpand
  • 61
  • 4
Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells--a potential mechanism for targeting liver anti-fibrotic therapeutics.
BACKGROUND/AIMS Hepatic stellate cells are pivotal to fibrogenesis in the liver and many potential anti-fibrotic therapeutics are required to act on targets within hepatic stellate cells. The aim ofExpand
  • 41
  • 2
Identification of a truncated ratp28-related protein expressed in kidney.
An RT-PCR based strategy to clone the membrane-associated steroid binding protein ratp28 additionally amplified a novel sequence-related PCR product termed HC5. The HC5 PCR product was cloned andExpand
  • 9
Low affinity glucocorticoid binding site ligands as potential anti-fibrogenics
BackgroundPregnane X receptor (PXR) agonists inhibit liver fibrosis. However, the rodent PXR activator pregnenolone 16α carbonitrile (PCN) blocks, in vitro, hepatic stellate cell-to-myofibroblastExpand
  • 12